ZCCHC10 as a novel prognostic biomarker associated with immune infiltration in breast cancer
It is suggested that ZCCHC10 serves as a prognostic biomarker and a key regulator of immune infiltration in breast cancer and Ipatasertib as a candidate targeted therapy requiring experimental verification.